Karuna Therapeutics KRTX signed a definitive merger agreement with Bristol Myers Squibb BMY. Per the agreement terms, Bristol Myers will acquire all outstanding shares of Karuna for $330 per share in ...

Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimer’s drugmaker Karuna Therapeutics for $14 billion. Bristol Myers said it would pay $330 a share cash for ...

Shares of Karuna Therapeutics KRTX have surged 98.7% in the past month against the industry’s 1.6% decline. One of the main reasons for this rise in stock price is management’s announcement of ...

Karuna Therapeutics was almost bought out by another large pharma that competed up until the last moment before Bristol Myers Squibb’s $14 billion proposal won out. The other multinational ...

Drugmaker Bristol Myers Squibb reached a deal to buy neuroscience-drug developer Karuna Therapeutics for $14 billion. Under the terms, Bristol would pay $330 a share in cash for Karuna and its ...

After launching on its maiden voyage in April, Seaport Therapeutics and its crew of Karuna veterans have loaded up with $225 million in series B funds to support the journey to key clinical milestones ...

Shares of Karuna Therapeutics Inc. KRTX rocketed 48% into record territory in premarket trading Friday, after the biopharmaceutical company announced an agreement to be bought by Bristol Myers Squibb ...

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and ...

To pay $330 a share in cash for Karuna Karuna's KarXT is a new type of antipsychotic medicine Analysts have forecast multi-billion dollars of peak KarXT sales Karuna's experimental schizophrenia drug, ...